Open access · CC-BY
via OpenAlex
The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS
Andrew Carter, Seth N Racey, Stephany Jane Veuger
Applied Sciences · 2022 · ▲ 33 citations
Abstract
Iron is a key metal involved in several biological processes such as DNA replication and repair, cellular proliferation and cell cycle regulation. Excess volumes of labile iron are toxic and can lead to the production of ROS (reactive oxygen species) via Fenton chemistry. Due to this reactive nature, it can contribute to DNA damage and genomic instability. Therefore, excess iron in the labile iron pool is associated with cancer, which has made the labile iron pool a crucial target for anticancer therapy by targeting iron. This iron can be incorporated into essential enzymes such as ribonucleotide reductase (RnR). Over several decades of research, iron chelators function as more than just RnR inhibitors. Indeed, a plethora of iron chelator mechanisms can result in therapeutic properties that can target critical steps of cancer cells’ aberrant biological abilities such as proliferation, migration and metastasis. One such mechanism is the production of redox-active complexes that can produce toxic levels of ROS in cancer cells. Cancer cells are potentially more susceptible to ROS production or modulation of antioxidant levels. Understanding iron metabolism is vital in targeting cancer. For instance, Fe-S clusters have recently been shown to play crucial roles in cell signalling by ROS through their incorporation into essential DNA replication and repair enzymes. ROS can also degrade Fe-S clusters. Iron chelators that produce toxic levels of ROS, therefore, could also target Fe-S centres. Thus, the design of iron chelators is important, as this can determine if it will participate in redox cycling and produce ROS or if it is solely used to remove iron. This review focuses on alterations in cancer iron metabolism, iron’s role in genomic stability and how the design of chelators can use Fenton chemistry to their advantage to cause DNA damage in cancer cells and potentially inhibit Fe-S centres.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/app121910161
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Carter, A., Racey, S.N., & Veuger, S.J. (2022). The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS. <em>Applied Sciences</em>. https://doi.org/10.3390/app121910161
Vancouver
Carter A, Racey SN, Veuger SJ. The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS. Applied Sciences. 2022. doi:10.3390/app121910161.
BibTeX
@article{andrew2022TheRol,
title = {The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS},
author = {Andrew Carter and Seth N Racey and Stephany Jane Veuger},
journal = {Applied Sciences},
year = {2022},
doi = {10.3390/app121910161},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Carolina Digital Repository (University of North Carolina at Chapel Hill) 2010
Preprint · OA
Chemical and Pharmacological Modulation of Telomerase
Cancers 2020
Open access · CC-BY
DNA Damage/Repair Management in Cancers
Antioxidants 2021
Open access · CC-BY
Oxidative Stress in Cancer Cell Metabolism
Journal of Hematology & Oncology 2025
Open access · CC-BY
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies
International Journal of Molecular Sciences 2023
Open access · CC-BY
Non-Genomic Hallmarks of Aging—The Review
International Journal of Molecular Sciences 2024
Open access · CC-BY